ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

ClinicalTrials.gov ID: NCT05180799

Public ClinicalTrials.gov record NCT05180799. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT05180799
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
BioAtla, Inc.
Industry
Enrollment
320 participants

Conditions and interventions

Interventions

  • BA3071 Biological
  • Nivolumab Biological
  • Pembrolizumab Biological
  • Pemetrexed (Alimta) Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2, 2022
Primary completion
Mar 18, 2025
Completion
Jun 29, 2026
Last update posted
Jun 14, 2025

2022 – 2026

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
The Angeles Clinic and Research Institute Los Angeles California 90025
USC Norris Comprehensive Cancer Center Los Angeles California 90033
Piedmont West Atlanta Georgia 30318
Northwest Cancer Centers Dyer Indiana 46311
Morristown Medical Center/Atlantic Health System Morristown New Jersey 07960
Icahn School of Medicine at Mt. Sinai New York New York 10029
University Hospitals Cleveland Medical Center Cleveland Ohio 44106
Providence Cancer Institute Portland Oregon 97213
University of Utah Huntsman Cancer Institute Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05180799, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 14, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05180799 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →